在EGFR+转移性NSCLC患者中中止奥西默提尼布后的治疗模式和资源使用
Elizabeth Marrett1, Winghan Jacqueline Kwong2, Jinlin Song3
1Health Economic and Outcomes Research, Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ, 07920, USA. elizabeth.marrett@daiichisankyo.com.
Oncology and therapy
|July 30, 2024
概括
在用 osimertinib 治疗 EGFR 突变非小细胞肺癌后的后续疗法往往是短暂的. 大多数患者接受基于的化疗,这凸显了针对EGFR氨酸激酶抑制剂耐药性的更有效治疗方法的未满足需求.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 目前的指导方针建议EGFR氨酸激酶抑制剂 (TKIs),特别是 osimertinib,用于EGFR突变转移性非小细胞肺癌 (mNSCLC) 的一线治疗.
- 对向疗法 (如奥西默提尼布) 的获得性耐药性是常见的,需要随后的治疗线路.
- 在针对性治疗进展后,通常建议进行全身化疗.
研究的目的:
- 在EGFR突变mNSCLC的患者中停止使用 osimertinib 后,描述随后的治疗线 (LOT).
- 评估治疗模式和随后治疗的持续时间.
- 确定管理EGFR TKI耐药性的未满足需求.
主要方法:
- 追溯分析医疗和药房索赔数据.
- 包括在2015年11月至2019年9月间停止服用奥西默提尼布后启动后续LOT的成年患者.
- 治疗方案,持续时间和医疗保健利用的特征.
主要成果:
- 135名患者符合纳入标准.
- 大多数患者 (57%) 在随后的LOT中接受了基于的化疗,其中40.3%包括免疫瘤治疗.
- 在24%的患者中观察到EGFR TKI重用或延续.
- 随后的LOT治疗中断的中位时间很短 (2.4个月).
- 显著比例的患者经历了住院 (31.9%) 或急诊室 (35.6%) 的访问.
结论:
- 在EGFR-mNSCLC中使用osimertinib后的后续疗法通常是短暂的.
- 耐受性问题似乎是导致治疗中止的重要因素.
- 对于克服EGFR TKI耐药性的新型治疗策略有很大的未满足需求.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:21Cancer Survival Analysis
336
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
336